Rockefeller Capital Management L.P. Puma Biotechnology, Inc. Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Mar 06, 2023	SELL	$2.12 - $5.08 $553 - $1,325	-261 Reduced 94.91%	14 $0
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $2,986 - $6,895	-1,048 Reduced 79.21%	275 $0
Q3 2021 Nov 12, 2021	SELL	$6.63 - $9.39 $369,814 - $523,764	-55,779 Reduced 97.68%	1,323 $9,000
Q2 2021 Aug 10, 2021	BUY	$8.98 - $11.6 $512,775 - $662,383	57,102 New	57,102 $524,000
Q4 2020 Feb 12, 2021	SELL	$7.78 - $12.13 $1,221 - $1,904	-157 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $551 - $646	58 Added 58.59%	157 $1,000
Q2 2020 Aug 12, 2020	SELL	$7.01 - $13.24 $448 - $847	-64 Reduced 39.26%	99 $1,000
Q1 2020 May 12, 2020	BUY	$6.28 - $14.57 $1,023 - $2,374	163 New	163 $1,000
Q4 2019 Feb 07, 2020	SELL	$6.5 - $10.73 $31,850 - $52,577	-4,900 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$8.75 - $12.85 $875 - $1,285	100 Added 2.08%	4,900 $53,000
Q4 2018 Feb 12, 2019	BUY	$20.07 - $46.7 $96,336 - $224,160	4,800 New	4,800 $98,000

102

29M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $138M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.